Login / Signup

Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes.

Rajiv AgarwalPatrick RossignolMartha R MayoAnsgar ConradSusan ArthurBryan WilliamsWilliam B White
Published in: Clinical journal of the American Society of Nephrology : CJASN (2021)
Keyphrases
  • blood pressure
  • type diabetes
  • chronic kidney disease
  • cardiovascular disease
  • glycemic control
  • phase iii
  • clinical trial
  • adipose tissue
  • arterial hypertension
  • skeletal muscle
  • weight loss
  • study protocol
  • double blind